Selective loss of dopamine D2 receptors in temporal cortex in dementia with Lewy bodies, association with cognitive decline

Synapse

Volumn 61, Issue 11, 2007, Pages 903-911

  Piggott, Margaret A ^a   Ballard, Clive G ^b   Rowan, Elise ^a   Holmes, Clive ^c   McKeith, Ian G ^a   Jaros, Evelyn ^a   Perry, Robert H ^a   Perry, Elaine K ^a  

^a NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c MOORGREEN HOSPITAL   (United Kingdom)

Author keywords

Alzheimer's disease; Autoradiography; Neuroleptic; Parkinson's disease; Psychosis

Indexed keywords

CHOLINESTERASE INHIBITOR; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR; EPIDEPRIDE; NEUROLEPTIC AGENT;

AGED; ALZHEIMER DISEASE; ARTICLE; AUDITORY HALLUCINATION; AUTOPSY; AUTORADIOGRAPHY; CHOLINERGIC ACTIVITY; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DELUSION; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DOPAMINE RELEASE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEWY BODY; MALE; NEOCORTEX; NEUROPATHOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; RECEPTOR DENSITY; SYMPTOMATOLOGY; TEMPORAL CORTEX; VISUAL HALLUCINATION;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BENZAMIDES; BRAIN CHEMISTRY; COGNITION DISORDERS; FEMALE; HUMANS; IODINE ISOTOPES; LEWY BODY DISEASE; MALE; POSTMORTEM CHANGES; PYRROLIDINES; RADIOGRAPHY; RECEPTORS, DOPAMINE D2; TEMPORAL LOBE;

EID: 34648816894     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20441     Document Type: Article

References (71)

1. Aarsland D, Perry R, Larsen JP, McKeith IG, O'Brien JT, Perry EK, Burn D, Ballard CG. 2005. Neuroleptic sensitivity in Parkinson's disease and Parkinsonian dementias. J Clin Psychiatry 66:633-637.
2. Antal A, Keri S, Bodis-Wollner I. 1997. Dopamine D2 receptor blockade alters the primary and cognitive components of visual evoked potentials in the monkey, Macaca fascicularis. Neurosci Lett 232:179-181.
3. Backman L, Nyberg L, Lindenberger U, Li S-C, Farde L. 2006. The correlative triad among aging, dopamine, and cognition: Current status and future prospects. Neurosci Biobehav Rev 30:791-807.
4. Ballard CG, Saad K, Patel A, Gahir M, Solis M, Coope B, Wilcock G. 1995. The prevalence and phenomenology of psychotic symptoms in dementia sufferers. Int J Geriatr Psychiatry 10:477-485.
5. Ballard C, McKeith I, Burn D, Harrison R, O'Brien J, Lowery K, Campbell M, Perry R, Ince P. 1997. The UPDRS scale as a means of identifying extrapyramidal signs in patients suffering from dementia with Lewy bodies. Acta Neurol Scand 96:366-371.
6. Ballard C, Holmes C, McKeith I, Neill D, O'Brien J, Cairns N, Lantos P, Perry E, Ince P, Perry R. 1999. Psychiatric morbidity in dementia with Lewy bodies: A prospective clinical and neuropathological comparative study with Alzheimer's disease. Am J Psychiatry 156:1039-1045.
7. Ballard C, Piggott M, Johnson M, Cairns N, Perry R, McKeith I, Jaros E, O'Brien J, Holmes C, Perry E. 2000. Delusions associated with elevated muscarinic M1 receptor binding in dementia with Lewy bodies. Ann Neurol 48:868-876.
8. Ballard CG, O'Brien JT, Swann AG, Thompson P, Neill D, McKeith IG. 2001. The natural history of psychosis and depression in dementia with Lewy bodies and Alzheimer's disease: Persistence and new cases over 1 year of follow-up. J Clin Psychiatry 62:46-49.
9. 123I]-epidepride single photon emission tomography (SPET) study. Br J Psychiatry 175:231-238.
10. Borrelli E. 2003. Dopamine D2 receptors: Key regulators of dopaminergic functions. J Neurochem 85:S2:5.
11. Braak H, Braak E. 1991. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239-259.
12. 123I] epidepride SPET study of amisulpride-treated patients. Am J Psychiatry 160:1413-1420.
13. Burns A, Jacoby R, Levy R. 1990a. Psychiatric phenomena in Alzheimer's disease. I. Disorders of thought content [see comments]. Br J Psychiatry 157:72-76, 92-74.
14. Burns A, Jacoby R, Levy R. 1990b. Psychiatric phenomena in Alzheimer's disease. II. Disorders of perception. Br J Psychiatry 157:76-81.
15. Burns A, Jacoby R, Levy R. 1990c. Psychiatric phenomena in Alzheimer's disease. III. Disorders of mood. Br J Psychiatry 157:81-86,92-84.
16. Burns A, Jacoby R, Levy R. 199Od. Psychiatric phenomena in Alzheimer's disease. IV. Disorders of behaviour. Br J Psychiatry 157:86-94.
17. Chui HC, Lyness SA, Sobel E, Schneider LS. 1994. Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer's disease. Arch Neurol 51:676-681.
18. Court JA, Lloyd S, Thomas N, Piggott MA, Marshall EF, Morris CM, Lamb H, Perry RH, Johnson M, Perry EK. 1998. Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use. Neuroscience 87:63-78.
19. Court JA, Ballard CG, Piggott MA, Johnson M, O'Brien JT, Holmes C, Cairns N, Lantos P, Perry RH, Jaros E, Perry EK. 2001. Visual hallucinations are associated with lower alpha bungarotoxin binding in dementia with Lewy bodies. Pharmacol Biochem Behav 70:571-579.
20. Devanand DP, Miller L, Richards M, Marder K, Bell K, Mayeux R, Stern Y. 1992. The Columbia University Scale for Psychopathology in Alzheimer's disease. Arch Neurol 49:371-376.
21. Dewey ME, Copeland JRM, Lobo A, Saz P, Dia JL. 1992. Computerized diagnosis from a standardized history schedule: A preliminary communication about the organic section of the HAS-AGE-CAT system. Int J Geriatr Psychiatry 7:443-446.
22. Drevets WC, Rubin EH. 1989. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type. Biol Psychiatry 25:39-48.
23. Duda JE, Giasson BI, Mabon ME, Lee VM, Trojanowski JQ. 2002. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol 52:205-210.
24. Förstl H, Besthorn C, Geiger-Kabisch C, Sattel H, Schreiter-Gasser U. 1993. Psychotic features and the course of Alzheimer's disease: Relationship to cognitive, electroencephalographic and computerized tomography findings. Acta Psychiatr Scand 87:395-399.
25. Glickstein SB, Hof PR, Schmauss C. 2002. Mice lacking dopamine D2 and D3 receptors have spatial working memory deficits. J Neurosci 22:5619-5629.
26. Goetz CG, Pappert EJ, Blasucci LM, Stebbins GT, Ling ZD, Nora MV, Carvey PM. 1998. Intravenous levodopa in hallucinating Parkinson's disease patients: High-dose challenge does not precipitate hallucinations. Neurology 50:515-517.
27. Goetz CG, Wuu J, Curgian L, Leurgans S. 2006. Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients. Mov Disord 21:267-270.
28. Goldsmith SK, Joyce JN. 1994. Dopamine D2 receptor expression in hippocampus and parahippocampal cortex of rat, cat and human in relation to tyrosine hydroxylase-immunoreactive fibres. Hippocampus 4:354-373.
29. Goldsmith SK, Shapiro RM, Joyce JN. 1997. Disrupted pattern of D2 dopamine receptors in the temporal lobe in schizophrenia - A postmortem study. Arch Gen Psychiatry 54:649-658.
30. Haeske-Dewick HC. 1995. Hallucinations in Parkinson's disease: Characteristics and associated clinical features. Int J Geriatr Psychiatry 10:487-495.
31. Haupt M, Romero B, Kurz A. 1996. Delusions and hallucinations in Alzheimer's disease: Results from a two-year longitudinal study. Int J Geriatr Psychiatry 11:965-972.
32. Henriksen A-L, St Dennis C, Setter SM, Tran JT. 2006. Dementia with Lewy bodies: Therapeutic opportunities and pitfalls. Consult Pharm 21:561-575.
33. Janowsky A, Neve KA, Kinzie JM, Taylor B, de Paulis T, Belknap JK. 1992. Extrastriatal dopamine D2 receptors: Distribution, pharmacological characterization and region-specific regulation by clozapine. J Pharmacol Exp Ther 261:1282-1290.
34. Joyce JN, Meador-Woodruff JH. 1997. Linking the family of D2 receptors to neuronal circuits in human brain: Insights into schizophrenia. Neuropsychopharmacology 16:375-384.
35. Joyce JN, Murray AM, Hurtig HI, Gottlieb GL, Trojanowski JQ. 1998a. Loss of dopamine D2 receptors in Alzheimer's disease with parkinsonism but not Parkinson's or Alzheimer's disease. Neuropsychopharmacology 19:472-480.
36. Joyce JN, Myers AJ, Gurevich E. 1998b. Dopamine D2 receptor bands in normal human temporal cortex are absent in Alzheimer's disease. Brain Res 784:7-17.
37. Kaasinen V, Nagren K, Hietala J, Oikonen V, Vilkman H, Farde L, Halldin C, Rinne JO. 2000. Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease. Neurology 54:1482-1487.
38. Kaasinen V, Aalto S, Nagren K, Hietala J, Sonninen P, Rinne JO. 2003. Extrastriatal dopamine D(2) receptors in Parkinson's disease: A longitudinal study. J Neural Trans 110:591-601.
39. Kemppainen N, Laine M, Laakso MP, Kaasinen V, Nagren K, Vahlberg T, Kurki T, Rinne JO. 2003. Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease. Eur J Neurosci 18:149-154.
40. 125I]epidepride. Brain Res 609:237-243.
41. Kobayashi A, Kawanishi C, Matsumura T, Kato D, Furukawa R, Kishida I, Hirayasu Y. 2006. Quetiapine-induced neuroleptic malignant Syndrome in dementia with Lewy bodies: A case report. Prog Neuro Psychopharmacol Biol Psychiatry 30:1170-1172.
42. Kovari E, Gold G, Herrmann FR, Canute A, Hof PR, Bouras C, Giannakopoulos P. 2003. Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's disease. Acta Neuropathol 106:83-88.
43. McKeith IG, Fairbairn AF, Perry R, Thompson P, Perry EK. 1992. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. Br Med J 305:673-678.
44. McKeith IG, Ballard CG, Harrison RW. 1995. Neuroleptic sensitivity to risperidone in Lewy body dementia. Lancet 346:699.
45. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH. 1996. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 47:1113-1124.
46. McKeith IG, Perry EK, Perry RH. 1999. Report of the second dementia with Lewy body international workshop: Diagnosis and treatment. Consortium on dementia with Lewy bodies. Neurology 53:902-905.
47. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R. 2000. Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study [comment]. Lancet 356:2031-2036.
48. McKeith IGMDF, Dickson DWM, Lowe JD, Emre MM, O'Brien JTD, Feldman HM, Cummings JM, Duda JEM, Lippa CM, Perry EKD, Aarsland DM, Arai HM, Ballard CGM, Boeve BM, Burn DJF, Costa DM, Del Ser TMDP, Dubois BM, Galasko DM, Gauthier SMF, Goetz CGM, Gomez-Tortosa EMDP, Halliday GP, Hansen LAM, Hardy JP, Iwatsubo TM, Kalaria RNF, Kaufer DM, Kenny RAM, Korczyn AM, Kosaka KM, Lee VMYPMBA, Lees AM, Litvan IM, Londos EMDP, Lopez OLM, Minoshima SMDP, Mizuno YM, Molina JAM, Mukaetova-Ladinska EBMDP, Pasquier FMDP, Perry RHD, Schulz JBM, Trojanowski JQMDP, Yamada MMDP, for the Consortium on DLB. 2005. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium. Neurology 65:1863-1872.
49. McShane R, Keene J, Gedling K, Fairburn C, Jacoby R, Hope T. 1997. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up [comment]. Br Med J 314:266-270.
50. Martin-Ruiz C, Lawrence S, Piggott M, Kuryatov A, Lindstrom J, Gotti C, Cookson MR, Perry RH, Jaros E, Perry EK, Court JA. 2002. Nicotinic receptors in the putamen of patients with dementia with Lewy bodies and Parkinson's disease: Relation to changes in alpha-synuclein expression. Neurosci Lett 335:134-138.
51. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L. 1991. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), Part 2: Standardization of the neuropathology assessment of Alzheimer's disease. Neurology 41:479-486.
52. 2 receptors to mesostriatal regions of human forebrain. Proc Natl Acad Sci USA 91:11271-11275.
53. Papapetropoulos S, Argyriou AA, Ellul J. 2005. Factors associated with drug-induced visual hallucinations in Parkinson's disease. J Neurol 252:1223-1228.
54. Perry EK, Kerwin J, Perry RH, Irving D, Blessed G, Fairbairn A. 1990a. Cerebral cholinergic activity is related to the incidence of visual hallucinations in senile dementia of Lewy body type. Dementia 1:2-4.
55. Perry EK, Marshall E, Kerwin J, Smith CJ, Jabeen S, Cheng AV, Perry RH. 1990b. Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem 55:1454-1456.
56. Perry EK, Smith CJ, Court JA, Perry RH. 1990c. Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types. J Neural Trans [Parkinson's Disease and Dementia Section] 2:149-158.
57. Perry RH, Irving D, Blessed G, Fairbairn A, Perry EK. 199Od. Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci 95:119-139.
58. Piggott MA, Perry EK, Marshall EF, McKeith IG, Johnson M, Melrose HL, Court JA, Lloyd S, Fairbairn A, Brown A, Thompson P, Perry RH. 1998. Nigrostriatal dopaminergic activities in dementia with Lewy bodies in relation to neuroleptic sensitivity: Comparisons with Parkinson's disease. Biol Psychiatry 44:765-774.
59. Piggott MA, Marshall EF, Thomas N, Lloyd S, Court JA, Jaros E, Burn D, Johnson M, Perry RH, McKeith IG, Ballard C, Perry EK. 1999. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: Rostrocaudal distribution. Brain 122 (Part 8):1449-1468.
60. Robbins TW 2000. Chemical neuromodulation of frontal-executive functions in humans and other animals. Exp Brain Res 133:130-138.
61. Rosen J, Zubenko GS. 1991. Emergence of psychosis and depression in the longitudinal evaluation of Alzheimer's disease. Biol Psychiatry 29:224-232.
62. Scheepmaker AJTM, Horstink MWIM, Hoefnagels WHL, Strijks FE. 2003. [Dementia with Lewy bodies; 2 patients with exacerbation due to an atypical antipsychotic, but with a favorable response to the Cholinesterase inhibitor rivastigmine] [see comment]. Nederlands Tijdschrift voor Geneeskunde 147:32-35.
63. Smith JW, Fetsko LA, Xu R, Wang Y. 2002. Dopamine D2L receptor knockout mice display deficits in positive and negative reinforcing properties of morphine and in avoidance learning. Neuroscience 113:755-765.
64. Steele C, Rovner B, Chase GA, Folstein M. 1990. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 147:1049-1051.
65. Suhara T, Okubo Y, Yasuno F, Sudo Y, Inoue M, Ichimiya T, Nakashima Y, Nakayama K, Tanada S, Suzuki K, Halldin C, Farde L. 2002. Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia [comment]. Arch Gen Psychiatry 59:25-30.
66. Sweet RA, Nimgaonkar VL, Kamboh MI, Lopez OL, Zhang F, DeKosky ST. 1998. Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer disease. Arch Neurol 55:1335-1340.
67. Sweet RA, Hamilton RL, Healy MT, Wisniewski SR, Henteleff R, Pollock BG, Lewis DA, DeKosky ST. 2001. Alterations of striatal dopamine receptor binding in Alzheimer disease are associated with Lewy body pathology and antemortem psychosis. Arch Neurol 58:466-472.
68. Thomas AJ, Burn DJ, Rowan EN, Littlewood E, Newby J, Cousins D, Pakrasi S, Richardson J, Sanders J, McKeith IG. 2005. A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry 20:938-944.
69. Wall PM, Blanchard RJ, Yang M, Blanchard DC. 2003. Infralimbic D2 receptor influences on anxiety-like behavior and active memory/attention in CD-1 mice. Prog Neuropsychopharmacol Biol Psychiatry 27:395-410.
70. Zoldan J, Friedberg G, Weizman A, Melamed E. 1996. Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-dopa therapy in advanced Parkinson's disease. Adv Neurol 69:541-544.
71. Zubenko GS, Moossy J, Martinez AJ, Rao G, Claassen D, Rosen J, Kopp U. 1991. Neuropathologic and neurochemical correlates of psychosis in primary dementia [published erratum appears in Arch Neurol 1992;49:1064]. Arch Neurol 48:619-624.